Harriet M. Kluger
Yale Cancer Center(US)Yale University(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Nivolumab plus Ipilimumab in Advanced Melanoma(2013)4,206 cited
- → Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab(2014)2,197 cited
- → PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma(2016)1,234 cited
- → Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma(2012)1,178 cited
- → Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial(2016)990 cited
- → Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors(2018)567 cited
- → Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial